We would like to use third party cookies for our own marketing purposes. We do not monetise your data otherwise.
Industries
About Us
Our Work
Blog
19 Mar 2026
What separates NVIDIA data centre GPUs from GeForce cards, how to read their names, what drives cloud computing GPU prices, and when renting beats buying.
16 Mar 2026
Which is better, CUDA or OpenCL? CUDA is usually faster on NVIDIA; OpenCL buys vendor reach at a per-device tuning cost. Profile before you commit.
16 Feb 2026
Plan GPU memory before a training run: estimate weights, activations, optimiser state, and workspace so jobs do not crash on OOM.
11 Feb 2026
How CUDA shapes AI inference latency on GPUs: precision, kernel fusion, interconnects, and the operational tradeoffs that decide cost per request.
4 Feb 2026
Why AI's black box problem matters, how it affects real-world systems, and what organisations can do to manage opacity in deep models.
3 Feb 2026
A 2026 guide to how augmented reality works: the AR stack, devices that matter, where it pays off, and how to scope a first deployment.
30 Jan 2026
Machine learning at the edge cuts decision delay by skipping the network, but hardware, compression and runtime decide whether a deployment works.
27 Jan 2026
How deep learning measures object size: detection vs segmentation, multi-scale features, ROI refinement, and where each approach fits inspection workflows.
21 Jan 2026
GPU-accelerated ML with NVIDIA cuML for inference latency: diagnose bottlenecks, choose quantisation, batching, and when to optimise vs add GPUs.
20 Jan 2026
AMD ROCm vs NVIDIA CUDA for AI in 2026: where measured results show ROCm behind, how PyTorch differs, what HIP porting involves, and how to benchmark…
19 Jan 2026
Best practices for training deep learning models, in order: validate data, start small, set learning rate and warmup, catch overfitting, checkpoint safely.
15 Jan 2026
A practical guide to GPU benchmarks for AI: what to measure, how to run fair tests, and how to turn results into procurement and SLA decisions.
14 Jan 2026
How to prove a GPU pricing or risk port is numerically safe: an agreed tolerance, a full-book parity harness, noise-versus-bug triage and a CI gate.
12 Jan 2026
Performance engineering for deep learning starts with profiling utilisation — not buying more GPUs.
10 Jan 2026
CPU vs GPU vs TPU for AI: the winner flips with batch size, model type, latency limits and precision, so headline speedups mislead.
TPU vs GPU for AI training and inference: architecture, energy efficiency, total cost, and ecosystem trade-offs explained for serious engineering teams.
9 Jan 2026
How energy-efficient GPUs cut power draw for ML training and inference without sacrificing throughput — precision, batching, and scheduling levers.
8 Jan 2026
OpenCL vs Vulkan, SYCL or CUDA: pick by workload and target, then port CUDA kernels one at a time and measure the delta on your own hardware.
When algorithmic restructuring beats kernel tuning for GPU speedups, with genomic analysis as the worked example.
7 Jan 2026
Where algorithmic restructuring beats kernel tuning in drug discovery: layout, batching, and decomposition choices that drive real GPU speedups.
6 Jan 2026
Where GPUs matter in healthcare AI: profiling the real latency bottleneck before scaling out, from medical imaging to genomics pipelines.
5 Jan 2026
Data visualisation in clinical research as the practice that turns trial data into decisions: methodology, GxP fit, and a credible 12-month roadmap.
19 Dec 2025
How computer vision supports modern clinical trials: imaging endpoints, OCR for trial documents, site logistics, and the regulatory frame that constrains…
18 Dec 2025
AI in bioinformatics helps with variant calling and evidence synthesis, but only when data quality, provenance and expert review come first.
17 Dec 2025
How biomedical computer vision pipelines move from research models to clinical-grade systems
16 Dec 2025
How AI is reshaping biotech research — protein modelling, genomic analysis, lab automation, and the pharma-manufacturing applications now in production.
15 Dec 2025
Machine learning in pharma analytics pays off first in manufacturing quality and yield, if data is fit for purpose and patterns survive leakage checks.
12 Dec 2025
Rare disease AI ranks diagnoses well on benchmarks, but plain LLMs trail Exomiser and no study has prospective validation. What the evidence shows.
11 Dec 2025
GenAI in drug discovery and medical imaging 2026: where it ships, where it stalls, regulatory-grade integration, AlphaFold-class tools in pipelines.
10 Dec 2025
AI biotech applications in real use today, from drug discovery to protein design and lab operations, and why most pilots stall before production.
8 Dec 2025
Why pharma delays AI adoption, what the delay costs in human error and scrap, and how to start without disrupting validated GxP workflows.
5 Dec 2025
AI in life sciences pays off upstream — sequence pattern recognition, automated QC, predictive analytics — long before drug-discovery moonshots.
4 Dec 2025
Pharma AI adoption delay 2026: regulatory misperception, over-scoping, transformation theatre, the costs of waiting, non-GxP starting points.
2 Dec 2025
A core visual aid carries a pharma brand's full detailing story. How IVAs, e-detailing and Veeva CLM deliver and track it, and what CV and AR add.
1 Dec 2025
How CV-based automated visual inspection replaces manual pharma QC: defect classes, GMP validation, AI vs deterministic vision, and cost realities.
27 Nov 2025
Pharmaceutical inspections and compliance essentials for AI-assisted batch release: what inspectors examine and the minimum tamper-evident audit trail.
26 Nov 2025
Where rule-based machine vision fits pharma manufacturing inspection — and where a custom computer vision system earns its place.
25 Nov 2025
Aseptic AI line monitoring 2026: line-section-first methodology, Annex 1 evidence, continuous vs batch validation, contractable fill-finish KPIs.
21 Nov 2025
AI for bioinformatics and lab automation in 2026: workflows with ROI today, pattern recognition at scale, modern automated labs, reproducibility.
20 Nov 2025
How AI in pharma quality control and manufacturing differs from AI in discovery: real-time release, deviation prediction, and the GxP validation envelope.
19 Nov 2025
Generative AI in drug discovery — what ships vs what's experimental: imaging, manufacturing differences, revenue applications, AlphaFold integration.
17 Nov 2025
Edge CV deployment in 2026: latency-accuracy-power trade-offs, Jetson vs NCS vs Coral, edge-vs-cloud economics, and architecture patterns that survive.
14 Nov 2025
AI drug discovery 2026: where CV sits in the pipeline, clinical-stage candidates vs platforms, screening integration, breakdown points, scaling.
12 Nov 2025
Where computer vision in healthcare is used and what must exist first: external validation, representative data, audit trails and human oversight.
11 Nov 2025
Automated visual inspection in pharma QC: defect classes, deployment cost, GMP validation, and when AI beats deterministic machine vision.
10 Nov 2025
Why CV systems trained on benchmarks fail on real inputs, and how biology-inspired attention and context modelling close the gap.
7 Nov 2025
Visual analytic intelligence for neural networks: how activation maps, attribution methods, and embedding projections expose what a model learned and…
6 Nov 2025
How visual computing supports real-time imaging, inspection and decisions on the pharma manufacturing line — proven use cases, not lab demos.